Investor Relations

Recent Event

Second Quarter 2020 Conference Call

mail icon

Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Medexus Pharmaceuticals Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
1 Place du Commerce
Suite 225
Verdun, QC H3E 1A2
Canada

Investor Relations (US)

Crescendo Communications, LLC
David Waldman / Natalya Rudman
T: 212-671-1020
mdp@crescendo-ir.com

Investor Relations (Canada)

Direct Financial Strategies and Communication Inc.
Frank Candido
T: 514-969-5530
frank.candido@medexus.com